I said before that I'm concerned that with all the agreements with Daiichi Sankyo that they may some day arquire Arqule. Now another agreement for ARQ 092. Now believe it's just a matter of time. Agree?
Once ARQ-197 completes it phase 3 study, and the results are positive, then I think that Sankyo will likely make a bid after FDA approval is granted...
Someone must read legal partnership documents explicitly specifying conditions when & how ArQule can be acquired by Daiichi
Agree ... Daiichi Sankyo is Japan's #2 pharma with a$15B market cap. No problem if they want to.